Activin-A binds follistatin and type II receptors through overlapping binding sites: Generation of mutants with isolated binding activities

Endocrinology

Volumn 147, Issue 6, 2006, Pages 2744-2753

  Harrison, Craig A ^a   Chan, Karen L ^a   Robertson, David M ^a  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXY 1 METHYLTETRALIN; ACTIVIN A; ACTIVIN RECEPTOR 1; ACTIVIN RECEPTOR 2; ALANINE; AMINO ACID; FOLLISTATIN; FOLLITROPIN;

ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG SYNTHESIS; GENE MUTATION; GONADOTROPIN SECRETING CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MUTAGENESIS; PRIORITY JOURNAL; PROTEIN INTERACTION; SCREENING;

ACTIVIN RECEPTORS, TYPE II; ACTIVINS; BINDING SITES; BINDING, COMPETITIVE; FOLLISTATIN; HUMANS; INHIBIN-BETA SUBUNITS; MUTAGENESIS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33646811178     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2006-0131     Document Type: Article

References (38)

1. Phillips DJ 2000 Regulation of activin's access to the cell: why is mother nature such a control freak? Bioessays 22:689-696
2. Vale W, Rivier C, Hsueh A, Campen C, Meunier H, Bicsak T, Vaughan J, Corrigan A, Bardin W, Sawchenko P, Petraglia F, Yu J, Plotsky P, Spiess J, Rivier J 1988 Chemical and biological characterization of the inhibin family of protein hormones. Recent Prog Horm Res 44:1-34
3. Eto Y, Tsuji T, Takezawa M, Takano S, Yokogawa Y, Shibai H 1987 Purification and characterization of erythroid differentiation factor (EDF) isolated from human leukemia cell line THP-1. Biochem Biophys Res Commun 142:1095-1103
4. Matzuk MM, Finegold MJ, Su JGJ, Hsueh AJW, Bradley A 1992 α-Inhibin is a tumor-suppressor gene with gonadal specificity in mice. Nature 366:313-319
5. Jones KL, de Kretser DM, Patella S, Phillips DJ 2004 Activin A and follistatin in systemic inflammation. Mol Cell Endocrinol 225:119-125
6. Ogawa Y, Schmidt DK, Nathan RM, Armstrong RM, Miller KL, Sawamura SJ, Ziman JM, Erickson KL, Deleon ER, Rosen DM, Seyedin S, Glaser C, Chang R, Corrigan A, Vale W 1992 Bovine bone activin enhances bone morphogenetic protein-induced ectopic bone formation. J Biol Chem 267:14233-14237
7. McCarthy SA, Bicknell R 1993 Inhibition of vascular endothelial cell growth by activin-A. J Biol Chem 268:23066-23071
8. Schubert D, Kimura H, LaCorbiere M, Vaughan J, Karr D, Fischer WH 1990 Activin is a nerve cell survival molecule. Nature 344:868-870
9. Beer HD, Gassmann MG, Munz B, Steiling H, Engelhardt F, Bleuel K, Werner S 2000 Expression and function of keratinocyte growth factor and activin in skin morphogenesis and cutaneous wound repair. J Investig Dermatol Symp Proc 5:34-39
10. Massague J 2000 How cells read TGFβ signals. Nat Rev Mol Cell Biol 1:169-178
11. Greenwald J, Groppe J, Gray P, Wiater E, Kwiatkowski W, Vale W, Choe S 2003 The BMP7/ActRII extracellular domain complex provides new insights into the cooperative nature of receptor assembly. Mol Cell 11:605-617
12. Mathews LS 1994 Activin receptors and cellular signaling by the receptor serine kinase family. Endocr Rev 15:310-325
13. Thompson TB, Woodruff TK, Jardetzky TS 2003 Structures of an ActRIIB: activin A complex reveal a novel binding mode for TGFβ ligand:receptor interactions. EMBO J 22:1555-1566
14. Harrison CA, Gray PC, Fischer WH, Donaldson C, Choe S, Vale W 2004 An activin mutant with disrupted ALK4 binding blocks signaling via type II receptors. J Biol Chem 279:28036-28044
15. Kirsch T, Sebald W, Dreyer MK 2000 Crystal structure of the BMP-2-BRIA ectodomain complex. Nat Struct Biol 7:492-496
16. Phillips DJ, de Kretser DM 1998 Follistatin: a multifunctional regulatory protein. Front Neuroendocrinol 19:287-322
17. Sidis Y, Tortoriello DV, Holmes WE, Pan Y, Keutmann HT, Schneyer AL 2002 Follistatin-related protein and follistatin differentially neutralize endogenous vs. exogenous activin. Endocrinology 143:1613-1624
18. Hashimoto O, Nakamura T, Shoji H, Shimasaki S, Hayashi Y, Sugino H 1997 Anovel role of follistatin, an activin-binding protein, in the inhibition of activin action in rat pituitary cells. Endocytotic degradation of activin and its acceleration by follistatin associated with cell-surface heparan sulfate. J Biol Chem 272:13835-13842
19. Wang Q, Keutmann HT, Schneyer AL, Sluss PM 2000 Analysis of human follistatin structure: identification of two discontinuous N-terminal sequences coding for activin A binding and structural consequences of activin binding to native proteins. Endocrinology 141:3183-3193
20. Keutmann HT, Schneyer AL, Sidis Y 2004 The role of follistatin domains in follistatin biological action. Mol Endocrinol 18:228-240
21. Thompson TB, Lerch TF, Cook RW, Woodruff TK, Jardetzky TS 2005 The structure of the follistatin:activin complex reveals antagonism of both type I and type II receptor binding. Dev Cell 9:535-543
22. Fischer WH, Park M, Donaldson C, Wiater E, Vaughan J, Bilezikjian LM, Vale, W 2003 Residues in the C-terminal region of activin A determine specificity for follistatin and type II receptor binding. J Endocrinol 176:61-68
23. Bittencourt JC, Presse F, Arias C, Peto C, Vaughan J, Nahon JL, Vale W, Sawchenko PE 1992 The melanin-concentrating hormone system of the rat brain: an immuno- and hybridization histochemical characterization. J Comp Neurol 319:218-245
24. van Casteren JI, Schoonen WG, Kloosterboer HJ 2000 Development of time-resolved immunofluorometric assays for rat follicle-stimulating hormone and luteinizing hormone and application on sera of cycling rats. Biol Reprod 62:886-894
25. Tsuchida K 2004 Activins, myostatin and related TGFβ family members as novel therapeutic targets for endocrine, metabolic and immune disorders. Curr Drug Targets Immune Endocr Metab Disord 4:157-166
26. Schneyer A, Schoen A, Quigg A, Sidis Y 2003 Differential binding and neutralization of activins A and B by follistatin and follistatin like-3 (FSTL-3/FSRP/FLRG). Endocrinology 144:1671-1674
27. Amthor H, Nicholas G, McKinnell I, Kemp CF, Sharma M, Kambadur R, Patel, K 2004 Follistatin complexes Myostatin and antagonises Myostatin-mediated inhibition of myogenesis. Dev Biol 270:19-30
28. Gamer LW, Cox KA, Small C, Rosen V 2001 Gdf11 is a negative regulator of chondrogenesis and myogenesis in the developing chick limb. Dev Biol 229:407-420
29. Glister C, Kemp CF, Knight PG 2004 Bone morphogenetic protein (BMP) ligands and receptors in bovine ovarian follicle cells: actions of BMP-4, -6 and -7 on granulosa cells and differential modulation of Smad-1 phosphorylation by follistatin. Reproduction 127:239-254
30. Matzuk MM, Lu N, Vogel H, Sellheyer K, Roop DR, Bradley A 1995 Multiple defects and perinatal death in mice deficient in follistatin. Nature 374:360-363
31. Iemura S, Yamamoto TS, Takagi C, Uchiyama H, Natsume T, Shimasaki S, Sugino H, Ueno, N 1998 Direct binding of follistatin to a complex of bone-morphogenetic protein and its receptor inhibits ventral and epidermal cell fates in early Xenopus embryo. Proc Natl Acad Sci USA 95:9337-9342
32. Muenster U, Harrison CA, Donaldson C, Vale W, Fischer WH 2005 An activin-A/C chimera exhibits activin and myostatin antagonistic properties. J Biol Chem 280:36626-36632
33. Canalis E, Economides AN, Gazzerro E 2003 Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr Rev 24:218-235
34. Govender S, Csimma C, Genant HK, Valentin-Opran A, Amit Y, Arbel R, Aro H, Atar D, Bishay M, Borner MG, Chiron P, Choong P, Cinats J, Courtenay B, Feibel R, Geulette B, Gravel C, Haas N, Raschke M, Hammacher E, van der Velde D, Hardy P, Holt M, Josten C, Ketterl RL, Lindeque B, Lob G, Mathevon H, McCoy G, Marsh D, Miller R, Munting E, Oevre S, Nordsletten L, Patel A, Pohl A, Rennie W, Reynders P, Rommens PM, Rondia J, Rossouw WC, Daneel PJ, Ruff S, Ruter A, Santavirta S, Schildhauer TA, Gekle C, Schnettler R, Segal D, Seiler H, Snowdowne RB, Stapert J, Taglang G, Verdonk R, Vogels L, Weckbach A, Wentzensen A, Wisniewski T 2002 Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am 84-A:2123-2134
35. Hirshberg J, Coleman J, Marchant B, Rees RS 2001 TGFβ3 in the treatment of pressure ulcers: a preliminary report. Adv Skin Wound Care 14:91-95
36. Munz B, Smola H, Engelhardt F, Bleuel K, Brauchle M, Lein I, Evans LW, Huylebroeck D, Balling R, Werner S 1999 Overexpression of activin A in the skin of transgenic mice reveals new activities of activin in epidermal morphogenesis, dermal fibrosis and wound repair. EMBO J 18:5205-5215
37. Wankell M, Munz B, Hubner G, Hans W, Wolf E, Goppelt A, Werner S 2001 Impaired wound healing in transgenic mice overexpressing the activin antagonist follistatin in the epidermis. EMBO J 20:5361-5372
38. Harrison CA, Gray PC, Vale WW, Robertson DM 2005 Antagonists of activin signaling: mechanisms and potential biological applications. Trends Endocrinol Metab 16:73-78